Stocks
Funds
Screener
Sectors
Watchlists
CVRX

CVRX - CVRx, Inc. Stock Price, Fair Value and News

$7.54+0.10 (+1.34%)
Market Closed

29/100

CVRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

29/100

CVRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CVRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CVRX Price Action

Last 7 days

-8.6%

Last 30 days

24.0%

Last 90 days

-10.8%

Trailing 12 Months

-31.8%

CVRX RSI Chart

CVRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CVRX Valuation

Market Cap

198.4M

Price/Earnings (Trailing)

-3.72

Price/Sales (Trailing)

3.5

EV/EBITDA

-3.62

Price/Free Cashflow

-4.87

CVRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CVRX Fundamentals

CVRX Revenue

Revenue (TTM)

56.7M

Rev. Growth (Yr)

4.45%

Rev. Growth (Qtr)

9.08%

CVRX Earnings

Earnings (TTM)

-53.3M

Earnings Growth (Yr)

-12.05%

Earnings Growth (Qtr)

7.27%

CVRX Profitability

Operating Margin

85.33%

EBT Margin

-94.13%

Return on Equity

-135.56%

Return on Assets

-50.87%

Free Cashflow Yield

-20.54%

CVRX Investor Care

Shares Dilution (1Y)

1.06%

Diluted EPS (TTM)

-2.04

CVRX Alerts

  • 1 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202552.9M54.7M56.0M56.7M
202442.1M44.4M47.3M51.3M
202326.4M30.8M35.2M39.3M
202214.3M16.2M19.0M22.5M
20217.8M9.5M11.3M13.0M
20200006.1M
CVRX
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
 CEO
 WEBSITEcvrx.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES160

CVRx, Inc. Frequently Asked Questions


CVRX is the stock ticker symbol of CVRx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of CVRx, Inc. is 198.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, CVRX's PE ratio (Price to Earnings) is -3.72 and Price to Sales (PS) ratio is 3.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CVRX PE ratio will change depending on the future growth rate expectations of investors.